| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
TRPC3/6/7 (Transient Receptor Potential Canonical 3, 6, and 7) ion channels. OptoBI-1 is a photoswitchable agonist that undergoes trans-to-cis isomerization at 365 nm (active cis form) and cis-to-trans isomerization at 430 nm (inactive trans form).
|
|---|---|
| ln Vitro |
Neuronal firing and endothelial Ca2+ transients are two TRPC3-linked cell activities that can be precisely and temporally controlled by OptoBI-1[1].
The active cis-form of OptoBI-1 activates TRPC3 with an EC50 of approximately 0.1 uM. It also activates TRPC6 and TRPC7 with similar potency. Under dark conditions (trans state), minimal agonist activity is observed. UV light exposure (365 nm) rapidly switches it to the active cis configuration, enabling precise channel activation. |
| ln Vivo |
In cellular systems, OptoBI-1 enables high-precision temporal control of TRPC3-linked cell functions, including neuronal firing and endothelial Ca2+ transients. In brain slices, light-activated OptoBI-1 triggers action potentials in neurons expressing TRPC3, providing a non-invasive method to control neuronal activity with millisecond precision.
|
| Enzyme Assay |
No specific cell-free receptor binding assays are applicable for OptoBI-1 as it is a photoswitchable small molecule that acts on ion channels. Photophysical characterization: absorption spectra are recorded using UV-Vis spectrophotometry before and after UV irradiation (365 nm) and visible light irradiation (430 nm) to confirm trans-cis isomerization.
|
| Cell Assay |
HEK293 cells heterologously expressing TRPC3 are loaded with a calcium-sensitive fluorescent dye (Fluo-4 AM). Cells are kept in the dark to maintain the inactive trans state. UV light (365 nm) is applied for 5-30 seconds to photoisomerize OptoBI-1 to its active cis form. Calcium influx is monitored by fluorescence microscopy in real time. To reverse activation, visible light (430 nm) is applied. EC50 is calculated based on fluorescence intensity vs. concentration of OptoBI-1. Whole-cell patch-clamp electrophysiology in TRPC3-expressing cells is performed to measure channel currents. Light-induced current activation is recorded using a programmable LED light source. For neuronal firing assays, primary hippocampal or cortical neurons expressing TRPC3 are loaded with a voltage-sensitive dye or recorded via patch-clamp. Action potentials are triggered by UV illumination and extinguished by blue light.
|
| Animal Protocol |
In vivo protocols involve transgenic mice expressing TRPC3 in specific neuronal populations (e.g., via AAV delivery). An optical fiber is implanted in the brain region of interest. OptoBI-1 is infused directly into the brain region via cannula or delivered systemically if BBB-permeable (unknown). For photostimulation, 365 nm LED is coupled to the fiber (pulse duration 1-100 ms, intensity 0.5-2 mW/mm2). Behavioral assays (locomotor activity, anxiety, learning) are performed during light stimulation. Electrophysiological recordings (local field potentials, single-unit activity) are obtained during photostimulation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for OptoBI-1 are not available. Given its photoswitchable nature and intended use as a photopharmacological tool, OptoBI-1 is typically delivered locally (e.g., intracerebral infusion) rather than systemically, making conventional PK parameters less relevant. Its stability in biological fluids and ability to cross the blood-brain barrier have not been characterized.
|
| Toxicity/Toxicokinetics |
No specific toxicity data have been reported. As a research tool used in localized brain infusion, systemic toxicity is less of a concern. Local toxicity assessment in brain tissue includes histological examination (neuronal death, glial activation, inflammation) after prolonged light exposure and compound infusion. Short-term use (hours) in slices and cell culture shows no overt toxicity. Long-term in vivo effects unknown.
|
| References | |
| Additional Infomation |
Other information: OptoBI-1 is a photopharmacological tool rather than a therapeutic drug. It is used to achieve spatiotemporal precision in neuronal control without genetic manipulation (unlike optogenetics). It is approved only for research use, not for clinical applications. Allows reversible control of TRPC3/6/7 channels with high temporal resolution (milliseconds).
|
| Molecular Formula |
C32H37N5O2
|
|---|---|
| Molecular Weight |
523.67
|
| Exact Mass |
523.294
|
| CAS # |
2415272-11-4
|
| PubChem CID |
146018968
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
7.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
39
|
| Complexity |
809
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC1=CC=C(C=C1)N=NC2=CC=C(C=C2)CCCC(=O)N3CCC(CC3)N4C5=CC=CC=C5NC4=O
|
| InChi Key |
LUASQYYRQCWOMA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H37N5O2/c1-2-3-7-24-12-16-26(17-13-24)34-35-27-18-14-25(15-19-27)8-6-11-31(38)36-22-20-28(21-23-36)37-30-10-5-4-9-29(30)33-32(37)39/h4-5,9-10,12-19,28H,2-3,6-8,11,20-23H2,1H3,(H,33,39)
|
| Chemical Name |
3-[1-[4-[4-[(4-butylphenyl)diazenyl]phenyl]butanoyl]piperidin-4-yl]-1H-benzimidazol-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9096 mL | 9.5480 mL | 19.0960 mL | |
| 5 mM | 0.3819 mL | 1.9096 mL | 3.8192 mL | |
| 10 mM | 0.1910 mL | 0.9548 mL | 1.9096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
